AHCLBSEANLON HEALTHCARE LIMITEDMediumNeutral
Announced Sat, 11 Jul · 16:17 IST

Anlon Healthcare incorporates 65 percent subsidiary Anlon Biologics

Listed Co AcquisitionStrategic Transactions View source PDF

AHCL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-3.3%1-day move
₹15.56
prior close
₹15.52
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.5+0.7+0.6-0.1-3.3-2.8-2.0-5.5-3.5-4.6
Up moveDown movePending
AI summary

ANLON HEALTHCARE has incorporated a new subsidiary called ANLON BIOLOGICS PRIVATE LIMITED on July 10, 2026. Anlon Healthcare holds a 65 percent stake, subscribing to 65,000 equity shares of Rs 10 each for a total cash investment of Rs 6.5 lakh. The new subsidiary will develop and manufacture peptides, biosimilars and biological products, expanding Anlon's pain management portfolio into the biologics segment. The subsidiary has authorized and paid-up share capital of Rs 10 lakh each and is yet to commence operations, so turnover is nil.

Likely market impact

Strategic entry into biologics and biosimilars segment expands future growth opportunities. Near-term financial impact is limited as the subsidiary is newly formed with nil revenue.